Canaccord Genuity Reiterates a 'Buy' on AtriCure (ATRC); ATRC Has Productive STS
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $48.98 +3.14%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on AtriCure Inc. (NASDAQ: ATRC) price target of $15.50.
Analyst, Jason R. Mills, said, "We believe ATRC has started 2012 well, with a spate of activities at the recent Society of Thoracic Surgeon (STS) meeting that we believe will reinvigorate the US surgical ablation market. We think ATRC is expanding its leadership position in market development of the concomitant ablation market. ATRC has numerous growth drivers in place both in the US and internationally (AtriClip, hybrid surgical/catheter procedure, A-Fib labeling, new product launches). We recommend investors continue to add to positions."
"Top--notch Maze IV training session. ATRC’s first training session post-approval (which we attended) was overbooked, with about 90 surgeons in attendance and a waiting list to participate. We think this is impressive given that Synergy has been in commercial use since 2001 in the US. We believe the program provided an excellent overview of concomitant ablation, patient selection, considerations for device selection, and expert advice on techniques."
For an analyst ratings summary and ratings history on AtriCure Inc. click here. For more ratings news on AtriCure Inc. click here.
Shares of AtriCure Inc. closed at $11.38 yesterday.
Analyst, Jason R. Mills, said, "We believe ATRC has started 2012 well, with a spate of activities at the recent Society of Thoracic Surgeon (STS) meeting that we believe will reinvigorate the US surgical ablation market. We think ATRC is expanding its leadership position in market development of the concomitant ablation market. ATRC has numerous growth drivers in place both in the US and internationally (AtriClip, hybrid surgical/catheter procedure, A-Fib labeling, new product launches). We recommend investors continue to add to positions."
"Top--notch Maze IV training session. ATRC’s first training session post-approval (which we attended) was overbooked, with about 90 surgeons in attendance and a waiting list to participate. We think this is impressive given that Synergy has been in commercial use since 2001 in the US. We believe the program provided an excellent overview of concomitant ablation, patient selection, considerations for device selection, and expert advice on techniques."
For an analyst ratings summary and ratings history on AtriCure Inc. click here. For more ratings news on AtriCure Inc. click here.
Shares of AtriCure Inc. closed at $11.38 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- DA Davidson Starts Everus (ECG) at Buy
- Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
